Predictive factors for the clinical effect of PD-1/PD-L1 checkpoint inhibitors in treatment of hepatocellular carcinoma / 临床肝胆病杂志
Journal of Clinical Hepatology
; (12): 1389-1392, 2020.
Article
de Zh
| WPRIM
| ID: wpr-822198
Bibliothèque responsable:
WPRO
ABSTRACT
At present, there is still a lack of uniform treatment strategies for hepatocellular carcinoma (HCC). Immunotherapy, especially PD-1/PD-L1 checkpoint inhibitors, is a novel therapy for HCC and can bring survival benefits to patients with advanced HCC. However, research data show that only a small number of HCC patients can benefit from this treatment regimen. To date, few biomarkers have been reported to predict the clinical effect of PD-1/PD-L1 checkpoint inhibitors in HCC patients. This article reviews the biomarkers studied for HCC and other tumors and explores the possible predictive factors for the clinical effect of PD-1/PD-L1 checkpoint inhibitors in HCC, in order to optimize the selection of treatment population and improve the clinical effect of PD-1/PD-L1 checkpoint inhibitors in the treatment of HCC.
Texte intégral:
1
Base de données:
WPRIM
Type d'étude:
Prognostic_studies
Langue:
Zh
Journal:
Journal of Clinical Hepatology
Année:
2020
Type de document:
Article